Reforms in Pharma on Snail Pace (India)
This article was originally published in PharmAsia News
Executive Summary
India-based pharmaceutical companies are calling on government officials to reform the country's price control policy. They claim the government does not take into account the costs of packaging when establishing price restrictions on drugs. Drug manufacturers say without this consideration, it is not cost effective to produce packaging necessary to discourage the sale of substandard imitation drugs. This leaves pharmaceutical companies with a major dilemma. They can either foot the cost of packaging or risk a glut of fraudulent drugs flooding the market. Representatives for India's pharmaceutical companies worry that to avoid this quandary some manufacturers will stop making price controlled products. Unfortunately, the 75 drugs on India's price controlled list, like Iron and Vitamin A supplements, are necessary for the health of the country's population. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.